Sigrid Therapeutics
Sigrid Therapeutics is a purpose-driven, consumer-focused healthtech company. They aim to prevent chronic lifestyle diseases such as obesity, type 2 diabetes, and heart disease. Their lead product candidate is SiPore21®, a breakthrough medical device for the safe reduction of blood sugar levels in individuals at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. SiPore21® is consumed orally as a tasty and easy-to-use gel. It has the potential to be the first treatment available for prediabetes, with the ability to prevent type 2 diabetes. Sigrid Therapeutics originated from research at Stockholm University and Karolinska Institute and is currently planning a new clinical trial called SHINE for their lead product candidate SiPore21®. They collaborate with various research institutions.